Methods for treatment of cancer with an anti-tigit antagonist antibody
US-2024424092-A1 · Dec 26, 2024 · US
Antibodies reactive with B7-H3, immunologically active fragments thereof and uses thereof
US9150656B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-9150656-B2 |
| Application number | US-201113581340-A |
| Country | US |
| Kind code | B2 |
| Filing date | Mar 1, 2011 |
| Priority date | Mar 4, 2010 |
| Publication date | Oct 6, 2015 |
| Grant date | Oct 6, 2015 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
The present invention relates to antibodies and their fragments that are immunoreactive to the mammalian, and more particularly, the human B7-H3 receptor and to uses thereof, particularly in the treatment of cancer and inflammation. The invention thus particularly concerns humanized B7-H3-reactive antibodies and their immunoreactive fragments that are capable of mediating, and more preferably enhancing the activation of the immune system against cancer cells that are associated with a variety of human cancers.
First claim
Opening claim text (preview).
What is claimed is: 1. An isolated antibody or an immunoreactive fragment thereof, wherein said isolated antibody or said fragment thereof comprises a variable domain that specifically binds an extracellular domain of B7-H3, wherein said antibody or said fragment thereof comprises a variable domain that comprises the amino acid sequences of: (A) CDR 1 (SEQ ID NO: 5), CDR 2 (SEQ ID NO: 7) and CDR 3 (SEQ ID NO: 9) of the light chain of BRCA84D; or (B) CDR 1 (SEQ ID NO: 13), C…
Assignees
Inventors
Classifications
Human Necessities · mapped topic
Human Necessities · mapped topic
Human Necessities · mapped topic
Chemistry & Metallurgy · mapped topic
Chemistry & Metallurgy · mapped topic
Patent family
Related publications grouped by family.
External sources
Next steps
Free tools are coming soon. Tell us what you want to track and we'll notify you.
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US9150656B2 cover?
- The present invention relates to antibodies and their fragments that are immunoreactive to the mammalian, and more particularly, the human B7-H3 receptor and to uses thereof, particularly in the treatment of cancer and inflammation. The invention thus particularly concerns humanized B7-H3-reactive antibodies and their immunoreactive fragments that are capable of mediating, and more preferably e…
- Who is the assignee on this patent?
- Johnson Leslie S, Moore Paul A, Huang Ling, and 3 more
- What technology area does this patent fall under?
- Primary CPC classification C07K16/2827. Mapped technology areas include Chemistry & Metallurgy.
- When was this patent published?
- Publication date Tue Oct 06 2015 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).